Want to see IRON full AI Analyst Report?
IRON Stock Chart & Stats
$71.77
$0.74(1.19%)
At close: 4:00 PM EST
$71.77
$0.74(1.19%)
Day’s Range― - ―
52-Week Range$40.00 - $99.50
Previous CloseN/A
Volume41.94K
Average Volume (3M)700.53K
Market Cap
$3.02B
Enterprise Value$2.62B
Total Cash (Recent Filing)$730.16M
Total Debt (Recent Filing)$31.06M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Aug 06, 2026EPS Estimate
-1.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.64
Shares Outstanding38,199,090
10 Day Avg. Volume948,470
30 Day Avg. Volume700,531
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-15.46
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.91K
Enterprise Value/Ebitda-11.01
Forecast
1Y Price Target
$101.50Price Target Upside41.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-6.94
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA sizable equity base (~$688M) and very low leverage provide durable funding capacity to support multi-year clinical programs. This improves the company’s ability to finance R&D, absorb trial setbacks, and negotiate partnerships without immediate refinancing pressure.
Expanded Debt FacilityThe Hercules amendment structurally extends access to debt tranches and delays covenant testing, materially improving liquidity runway. Extended tranche dates and a pushed covenant testing date reduce near-term funding risk and support uninterrupted development timelines.
Governance ContinuityRe-election of experienced directors, shareholder approval of executive compensation, and auditor ratification signal governance stability. This continuity supports consistent clinical strategy, oversight of trial execution, and reliable financial reporting over the medium term.
Bears Say
High Cash BurnSustained annual cash burn exceeding $200M creates persistent financing dependence and raises dilution risk if capital raises are required. High burn constrains optionality, forcing prioritization of programs and making long-term execution contingent on continued access to capital.
Pre-revenue StatusBeing pre-revenue leaves company value fully dependent on clinical and regulatory success. Without product sales, prolonged development timelines or trial setbacks could require repeated financing, increasing dilution and elevating the risk profile for investors over months.
Negative Returns On EquityA materially negative ROE indicates the company is consuming rather than compounding shareholder capital. This structural capital erosion suggests that, absent successful partnerships or commercialization, investor capital may continue to be diluted to fund operations.
Disc Medicine News
IRON FAQ
What was Disc Medicine, Inc.’s price range in the past 12 months?
Disc Medicine, Inc. lowest stock price was $40.00 and its highest was $99.50 in the past 12 months.
What is Disc Medicine, Inc.’s market cap?
Disc Medicine, Inc.’s market cap is $3.02B.
When is Disc Medicine, Inc.’s upcoming earnings report date?
Disc Medicine, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 25 days.
How were Disc Medicine, Inc.’s earnings last quarter?
Disc Medicine, Inc. released its earnings results on May 05, 2026. The company reported -$1.65 earnings per share for the quarter, missing the consensus estimate of -$1.645 by -$0.005.
Is Disc Medicine, Inc. overvalued?
According to Wall Street analysts Disc Medicine, Inc.’s price is currently Undervalued.
Does Disc Medicine, Inc. pay dividends?
Disc Medicine, Inc. does not currently pay dividends.
What is Disc Medicine, Inc.’s EPS estimate?
Disc Medicine, Inc.’s EPS estimate is -1.71.
How many shares outstanding does Disc Medicine, Inc. have?
Disc Medicine, Inc. has 38,199,090 shares outstanding.
What happened to Disc Medicine, Inc.’s price movement after its last earnings report?
Disc Medicine, Inc. reported an EPS of -$1.65 in its last earnings report, missing expectations of -$1.645. Following the earnings report the stock price went down -0.074%.
Which hedge fund is a major shareholder of Disc Medicine, Inc.?
Currently, no hedge funds are holding shares in IRON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Disc Medicine Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$101.50 (41.42% Upside)
$101.50 (41.42% Upside)
Blogger Sentiment
Bullish
IRON Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 246.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
32.05%
12-Months-Change
Fundamentals
Return on Equity
-36.95%
Trailing 12-Months
Asset Growth
5.77%
Trailing 12-Months
Company Description
Disc Medicine, Inc.
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
IRON Stock 12 Month Forecast
Average Price Target
$101.50
▲(41.42% Upside)
Technical Analysis
Agios Pharma
―
Travere Therapeutics
―
Arcutis Biotherapeutics
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
8.86% Insiders
27.28% Mutual Funds
1.07% Other Institutional Investors
50.22% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---